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Supervised Injection Facilities
Legal and Policy Reforms
The US Centers for Disease Control and Prevention
reported that more than 70 000 deaths from drug
overdoses occurred in 2017, including prescription and
illicit opioids, representing a 6-fold increase since
1999.1 Innovative harm-reduction solutions are impera-
tive. Supervised injection facilities (SIFs) create safe
places for drug injection, including overdose preven-
tion, counseling, and treatment referral services.
Supervised injection facilities neither provide illicit
drugs nor do their personnel inject users. Supervised
injection facilities are effective in reducing drug-related
mortality, morbidity, and needle-borne infections. Yet
their lawfulness remains uncertain. The Department of
Justice (DOJ) recently threatened criminal prosecution
for SIF operators, medical personnel, and patrons.
Public Health Foundations
One year after President Trump declared the opioid
crisis a public health emergency in October 2017, the
administration allocated $320 million for treatment
and enforcement. However, no direct funds were
devoted to harm reduction,2 characterized by the
Surgeon General as “public health-oriented and
cost-effective.”3 The American Medical Association,
among many health organizations, supports the cre-
ation of and funding for SIFs.4 Licensed personnel at
SIFs supervise clients’ drug injections and administer
naloxone or other lifesaving procedures when
needed. These interventions are similar to services
drug users receive from emergency medical person-
nel, but which often come too late after overdoses
involving high-potency heroin and fentanyl.
After the first SIF opened in Bern, Switzerland, in
1986, sites in multiple countries followed. As of April
2018, 78 official SIFs operated in Europe (Denmark,
France, Germany, Luxembourg,Norway, Spain, and the
Netherlands), as well as in Australia and Canada. Ire-
land and Portugal recently authorized SIFs.
ClandestineSIFshaveoperated in theUnitedStates
since2014.Similarpracticesareundertaken inother set-
tings; for example, a New York, New York, needle ex-
change program allows patrons to inject in its bath-
rooms, providing emergency services if necessary.
Although no state or locality openly operates SIFs, sev-
eral have proposed their creation (an eFigure map ap-
pears in the Supplement).
Public Health Benefits
Although the data are limited, SIFs provide public
health benefits and are associated with substantial
decreases in overdose fatalities among patrons and in
surrounding communities. A SIF in Sydney, Australia,
reported no deaths among 5925 overdoses from
965 000 supervised injections from 2001-2015.5
A SIF in Barcelona, Spain, reported a 50% reduction
in overdose mortality in the vicinity from 1991 (1833
deaths) to 2008 (773 deaths).6 Declines in publicly dis-
carded syringes have also been observed. Monthly
averages of unsafely disposed syringes collected
near the Barcelona SIF decreased from 13000 in 2004
to 3000 in 2012. Importantly, SIFs do not increase
overall drug or other related crime rates in surrounding
areas. To the contrary, the US-based clandestine SIF is
credited with averting an estimated
2300 public injections in proximity to
its location from 2014-2016.7
The Insite SIF in Vancouver, British
Columbia, Canada, is illustrative. No
fatal overdoses were reported between
March 2004 and February 2008.
Among a select group of 621 drug users
at the facil ity, 42% (261 persons)
entered addiction treatment during the
2 years since its opening in 2003.
Researchers also attribute Insite with preventing 80
HIV infections annually. Within 3 months of opening,
public injections in the surrounding 10 blocks
decreased by nearly half (from 4.3 to 2.4 per day).6
Community overdose deaths decreased 35% (from 254
to 165 deaths per 100000 persons) over 4 years start-
ing in 2001. Neighborhood rates of drug trafficking,
assault, and robbery did not increase after Insite
opened. Whether these same beneficial results would
occur in the United States needs to be tested.
Legal Controversy
Despitepublic healthbenefits, state and local efforts to
authorize SIFs have generated a legal and political
firestorm.Criticscharge that thegovernmentshouldnot
subsidize or incentivize harmful and unlawful behav-
iors. Some states have preempted the opening of SIFs.
In 2017, the municipalities of Kent and Snohomish in
WashingtonStaterestrictedzoningtoprohibit them.The
state’s supreme court is considering whether a SIF ban
should be put to a public vote. Additional concerns in-
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clude legal liability forhealthprofessionalsoverseeingorstaffingSIFs
and limitations on malpractice insurance coverage for engaging in
unlawful activities.
In late August 2018, Deputy Attorney General Rod Rosen-
stein characterized SIFs as “taxpayer-sponsored havens to shoot
up.” “Because federal law clearly prohibits injection sites,” he
argued, “[jurisdictions] should expect [DOJ] to meet the opening
of any [SIF] with swift and aggressive action.”8 Later, the DOJ
labeled New York City’s planned SIF as incompatible with appro-
priate opioid response efforts.
The DOJ claim that SIFs violate federal drug laws resulted in
state and local reluctance to open these facilities. The governor of
California vetoed legislation authorizing SIFs in San Francisco.
The governor of Pennsylvania said he could not support SIFs with-
out a change in federal law. Undeterred, San Francisco, California;
Philadelphia, Pennsylvania; Denver, Colorado; Seattle,Washington,
and other localities continue to explore the formation of SIFs.
Misapplication of Federal Criminal Laws
Courts have yet to review the DOJ interpretation of the Controlled
SubstancesAct (CSA),which prohibits any person frompossessing
illicitdrugsoroperatingplaces thatknowinglyallowuseof illicitdrugs
on the premises.
The CSA explicitly immunizes state, tribal, or local officers
“lawfully engaged in the enforcement of any law or municipal
ordinance relating to controlled substances.”9 Although this
immunity applies mainly to conducting drug investigations or
raids, it could offer a creative defense if states or localities autho-
rize SIFs. The DOJ, moreover, could decline to enforce federal
drug laws that are incompatible with state legalization of SIFs.
Despite its threats, for example, the DOJ has not aggressively
enforced federal laws in states that have legalized marijuana.
The CSA prohibition on premises allowing illicit drug use pre-
sents themost difficult legal challenge to SIFs. However, this provi-
sion is targeted historically against crack houses or other drug en-
claves, not public health enterprises. Supervised injection facilities
are not drug havens, but rather places to help safeguard the health
of the public. In April 2017, a Massachusetts task force character-
ized SIFs as medical treatment for at-risk patrons.
The Criminalization of Public Health
The criminalization of public health initiatives has a long, sordid
history, including resistance to needle exchanges and expedited
partner therapies. In each case, legislators and judges have come
to view criminal strategies as unjustified. Armed with evidence of
effectiveness, health officials have persuaded policy makers to
value harm reduction. Greater respect for states’ public health
powers could considerably narrow the DOJ’s ability to prosecute
SIF patrons and staff.
Use of SIFs for Research
If the DOJ persists in threatening prosecution of SIFs, states could
seek a research exemption under CSA §823(f), which permits gov-
ernment-funded public health studies. Registered health profes-
sionalsmayallowresearchparticipants touseheroinorother sched-
ule I drugs in the public’s interest. Establishing SIFs for express
research purposeswould help to build an evidence base that could
influence policy makers over the long-term.
Public Health Prevention and Response
Punitive drug laws have failed to curtail the opioid epidemic.
Whether SIFs will succeed in the United States is undetermined,
but harm-reduction strategies abroad have prevented overdose
deaths and promoted drug dependency treatment for decades.
Wise implementation of drug laws can be compatible with harm
reduction. In community settings, police could enforce the CSA,
bringing offenders before drug courts. These specialized courts
screen and assess health risks and needs using graduated sanc-
tions and incentives to usher offenders into treatment and reha-
bilitation. However, criminal law has no value in public health ini-
tiatives like SIFs designed to prevent harms and counsel clients.
The opioid crisis remains a national public health emergency that
demands therapeutic strategies guided by scientific evidence,
and not inappropriate applications of punitive criminal laws.
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